The role of novel cytokines in inflammation: Defining peripheral artery disease among patients with coronary artery disease

Gür, Demet Özkaramanlı; Güzel, Savaş; Akyüz, Aydın; Alpsoy, Şeref; Güler, Niyazi

doi:10.1177/1358863x18763096

Cited by 20 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiovascular diseases (CVDs), especially coronary artery disease (CAD), continue to be the major causes of deaths worldwide. CAD is caused by coronary atherosclerosis, an inflammatory disease resulting from the formation of plaques and subsequent obstruction of coronary arteries . Despite recent advances in the diagnosis, treatment and prognosis of cardiovascular diseases, there is still a clinical need to identify novel diagnostic and prognostic biomarkers that pave the way for new therapeutic interventions.…”

Section: Introductionmentioning

confidence: 99%

KCNQ1OT1, HIF1A‐AS2 and APOA1‐AS are promising novel biomarkers for diagnosis of coronary artery disease

Zhang

Wang

et al. 2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

This study aimed to evaluate the potential of long noncoding RNAs (lncRNAs) as biomarkers for coronary artery disease (CAD). We measured the levels of three atherosclerosis‐ or cardiac‐related lncRNAs in peripheral blood monocyte cells (PBMCs) from 20 CAD patients and 20 non‐CAD control participants using real‐time reverse transcription–polymerase chain reaction (real‐time RT–PCR) methods. We found that the levels of lncRNA KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1), hypoxia‐inducible factor 1 alpha‐antisense RNA 2 (HIF1A‐AS2) and apolipoprotein A‐1 antisense RNA (APOA1‐AS) were significantly increased in CAD patients (KCNQ1OT1 increased by 2.38‐fold, P = 0.00042; HIF1A‐AS2 increased by 2.00‐fold, P = 0.0001; APOA1‐AS increased by 4.52‐fold, P = 0.000048). The area under the ROC curve was 0.865 for KCNQ1OT1, 0.852 for HIF1A‐AS2, and 0.967 for APOA1‐AS. Furthermore, the combination of lncRNAs resulted in a much higher AUC value of 0.990 for the prediction of CAD. Spearman's correlation analysis showed that APOA1‐AS was positively correlated with NT‐proBNP, CKMB, MYO and HsTnT, whereas HIF1A‐AS2 was correlated with NT‐proBNP and HsTnT. Hence, the elevation of KCNQ1OT1, HIF1A‐AS2 and APOA1‐AS predicts CAD and these molecules may be considered as novel biomarkers of CAD.

show abstract

Section: Introductionmentioning

confidence: 99%

KCNQ1OT1, HIF1A‐AS2 and APOA1‐AS are promising novel biomarkers for diagnosis of coronary artery disease

Zhang

Wang

et al. 2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…Recent evidence proposes a critical role of inflammatory processes in the pathophysiology of PAD [12-15]. Platelets employ pattern recognition receptors toll-like receptor 4 (TLR4) and nucleotide-binding domain leucine rich repeat containing protein 3 (NLRP3) [16-19].…”

Section: Introductionmentioning

confidence: 99%

TLR4-dependent upregulation of the platelet NLRP3 inflammasome promotes platelet aggregation in a murine model of hindlimb ischemia

Vogel

Murthy

Cui

et al. 2019

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Platelets play a critical role in the pathophysiology of peripheral arterial disease (PAD). The mechanisms by which muscle ischemia regulates aggregation of platelets are poorly understood. We have recently identified the Nod-like receptor nucleotide-binding domain leucine rich repeat containing protein 3 (NLRP3) expressed by platelets as a critical regulator of platelet activation and aggregation, which may be triggered by activation of toll-like receptor 4 (TLR4). In this study, we performed femoral artery ligation (FAL) in transgenic mice with platelet-specific ablation of TLR4 (TLR4 PF4) and in NLRP3 knockout (NLRP3 −/−) mice. NLRP3 inflammasome activity of circulating platelets, as monitored by activation of caspase-1 and cleavage of interleukin-1β (IL-1β), was upregulated in mice subjected to FAL. Genetic ablation of TLR4 in platelets led to decreased platelet caspase 1 activation and platelet aggregation, which was reversed by the NLRP3 activator Nigericin. Two weeks after the induction of FAL, ischemic limb perfusion was increased in TLR4 PF4 and NLRP3 −/− mice as compared to control mice. Hence, activation of platelet TLR4/NLRP3 signaling plays a critical role in upregulating platelet aggregation and interfering with perfusion recovery in muscle ischemia and may represent a therapeutic target to improve limb salvage.

show abstract

“…found that the N‐terminal domain of Nogo‐A inhibits cell adhesion and axonal outgrowth through several integrins, including α v β 3 (Hu and Strittmatter, ). ER‐resident Nogo‐B protein can not only localize to the plasma membrane but also secrete into extracellular space (Acevedo et al ., ; Ozkaramanli Gur et al ., ). Nogo‐B in HCC cells exhibited a consistent distribution in our work, that it can be detected both on HCC cell surface and in the cell culture medium (data not shown).…”

Section: Discussionmentioning

confidence: 97%

Nogo‐B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma

et al. 2018

View full text Add to dashboard Cite

Tumor angiogenesis is one of the hallmarks of cancer as well as an attractive target for cancer therapy. Characterization of novel pathways that act in parallel with the VEGF/VEGFR axis to promote tumor angiogenesis may provide insights into novel anti‐angiogenic therapeutic targets. We found that the expression level of Nogo‐B is positively correlated with tumor vessel density in hepatocellular carcinoma (HCC). While Nogo‐B depletion inhibited tumor angiogenesis, Nogo‐B overexpression promoted tumor angiogenesis in a tumor xenograft subcutaneous model of the human HCC cell line. Mechanically, Nogo‐B regulates tumor angiogenesis based on its association with integrin αvβ3 and activation of focal adhesion kinase. Moreover, Nogo‐B antibody successfully abolished the function of Nogo‐B in tumor angiogenesis in vitro and in vivo. Collectively, our results strongly suggest that Nogo‐B is an important tumor angiogenic factor and blocking Nogo‐B selectively inhibits tumor angiogenesis.

show abstract

The role of novel cytokines in inflammation: Defining peripheral artery disease among patients with coronary artery disease

Cited by 20 publications

References 32 publications

KCNQ1OT1, HIF1A‐AS2 and APOA1‐AS are promising novel biomarkers for diagnosis of coronary artery disease

KCNQ1OT1, HIF1A‐AS2 and APOA1‐AS are promising novel biomarkers for diagnosis of coronary artery disease

TLR4-dependent upregulation of the platelet NLRP3 inflammasome promotes platelet aggregation in a murine model of hindlimb ischemia

Nogo‐B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma

Contact Info

Product

Resources

About